Literature DB >> 27492836

Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients.

Marieke G G Sturkenboom1, Onno W Akkerman2, Richard van Altena3, Wiel C M de Lange2, Jos G W Kosterink4, Tjip S van der Werf5, Jan-Willem C Alffenaar6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27492836     DOI： 10.1183/13993003.00986-2016

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  3 in total

1.  Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.

Authors:  Reihaneh Abolhassani-Chimeh; Onno W Akkerman; Antonia M I Saktiawati; Nieko C Punt; Mathieu S Bolhuis; Yanri W Subronto; Tjip S van der Werf; Jos G W Kosterink; Jan-Willem C Alffenaar; Marieke G G Sturkenboom
Journal:  Antimicrob Agents Chemother       Date:  2022-06-21       Impact factor: 5.938

2.  Development and performance of CUHAS-ROBUST application for pulmonary rifampicin-resistance tuberculosis screening in Indonesia.

Authors:  Bumi Herman; Wandee Sirichokchatchawan; Sathirakorn Pongpanich; Chanin Nantasenamat
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

3.  A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis.

Authors:  Stijn W van Beek; Rob Ter Heine; Jan-Willem C Alffenaar; Cecile Magis-Escurra; Rob E Aarnoutse; Elin M Svensson
Journal:  Clin Pharmacokinet       Date:  2021-02-22       Impact factor: 6.447
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.